



**MEDICAID / CHIP**  
**PHARMACY PRIOR AUTHORIZATION REQUEST FORM**

**Immunomodulators - Dermatologics**

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Member Name:	Prescriber Name:	
Member ID Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Member Phone Number:	NPI:	PA PROMISe ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Line of Business: <input type="checkbox"/> Medicaid <input type="checkbox"/> CHIP	Specialty Pharmacy (if applicable):	
Drug Name:	Strength:	
Quantity:	Refills:	
Directions:		
Diagnosis Code:	Diagnosis:	

*Jefferson Health Plans' maximum approval time is 12 months but may be less depending on the criteria..*

**Please attach any pertinent medical history including labs and information for this member that may support approval.**

***Please answer the following questions and sign.***

Q1. The request is for an Immunomodulators, Dermatologic that was previously approved. If YES, go to 24.

Yes

No

Q2. The member meets ALL of the following:

- Is prescribed the Immunomodulators Dermatologic for the treatment of a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling or a medically accepted indication
- Is age-appropriate according to FDA-approved package labeling, national compendia, or peer-reviewed medical literature
- Is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature
- Does not have a contraindication to the requested drug

Q3. What type of drug is being requested?

- For a non-preferred topical calcineurin inhibitor, go to 4.
- For a topical PDE4 inhibitor (e.g., crisaborole, roflumilast), go to 5.
- For a topical JAK inhibitor (e.g., ruxolitinib), go to 8.
- For a topical AhR agonist (e.g., tapinarof), go to 11.



**MEDICAID / CHIP**  
**PHARMACY PRIOR AUTHORIZATION REQUEST FORM**

**Immunomodulators - Dermatologics**

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Member Name:	Prescriber Name:
--------------	------------------

- For all other non-preferred topical Immunomodulators, Dermatologics, go to 15.
- For a targeted systemic Immunomodulators, Dermatologic, go to 16

Q4. For a non-preferred topical calcineurin inhibitor, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred topical calcineurin inhibitors.

- Yes  No

Q5. For a topical PDE4 inhibitor (e.g., crisaborole, roflumilast), for treatment of atopic dermatitis, has a history of therapeutic failure of or a contraindication or an intolerance to both of the following:

- A four-week trial of a topical corticosteroid approved or medically accepted for the treatment of the beneficiary's diagnosis
- An eight-week trial of a topical calcineurin inhibitor approved or medically accepted for the treatment of the beneficiary's diagnosis.

Q6. For a topical PDE4 inhibitor (e.g., crisaborole, roflumilast), for treatment of all other diagnoses, has a history of therapeutic failure of or a contraindication or an intolerance to first line therapy(ies) if applicable according to consensus treatment guidelines.

- Yes  No

Q7. For a non-preferred topical PDE4 inhibitor, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred topical PDE4 inhibitors approved or medically accepted for the beneficiary's diagnosis. Describe all applicable medical reasons the beneficiary cannot use the preferred medication(s) in the same class. Submit documentation (e.g., recent chart/clinic notes, diagnostic evaluations, lab results, etc.) supporting this non-preferred request. Include drug name, dose, and start/stop dates.

- Yes  No

Q8. For a topical JAK inhibitor (e.g., ruxolitinib), for treatment of atopic dermatitis, chronic hand eczema, or vitiligo, has a history of therapeutic failure of or a contraindication or an intolerance to both of the following:

- A four-week trial of a topical corticosteroid approved or medically accepted for the treatment of the beneficiary's diagnosis
- An eight-week trial of a topical calcineurin inhibitor approved or medically accepted for the treatment of the beneficiary's diagnosis.

**Immunomodulators - Dermatologics**

**Phone: 866-841-7659**

**Fax back to: 866-240-3712**

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Member Name:	Prescriber Name:
--------------	------------------

Q9. For a topical JAK inhibitor (e.g., ruxolitinib), for treatment of all other diagnoses, has a history of therapeutic failure of or a contraindication or an intolerance to first line therapy(ies) if applicable according to consensus treatment guidelines.

Yes

No

Q10. For a non-preferred topical JAK inhibitor, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred topical JAK inhibitors approved or medically accepted for the beneficiary's diagnosis

Yes

No

Q11. For a topical AhR agonist (e.g., tapinarof), for treatment of atopic dermatitis, has a history of therapeutic failure of or a contraindication or an intolerance to both of the following:

A four-week trial of a topical corticosteroid approved or medically accepted for the treatment of the beneficiary's diagnosis

An eight-week trial of a topical calcineurin inhibitor approved or medically accepted for the treatment of the beneficiary's diagnosis.

Q12. For treatment of psoriasis, see the prior authorization guideline for Antipsoriatics, Topical. For treatment of all other diagnoses, go to 13.

Yes

No

Q13. For treatment of all other diagnoses, has a history of therapeutic failure of or a contraindication or an intolerance to first line therapy(ies) if applicable according to consensus treatment guidelines.

Yes

No

Q14. For a non-preferred topical AhR agonist, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred topical AhR agonists approved or medically accepted for the beneficiary's diagnosis.

Yes

No

Q15. For all other non-preferred topical Immunomodulators, Dermatologics, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred topical Immunomodulators, Dermatologics approved or medically accepted for the beneficiary's

## Immunomodulators - Dermatologics

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Member Name:	Prescriber Name:
--------------	------------------

diagnosis. Describe all applicable medical reasons the beneficiary cannot use the preferred medication(s) in the same class. Submit documentation (e.g., recent chart/clinic notes, diagnostic evaluations, lab results, etc.) supporting this non-preferred request. Include drug name, dose, and start/stop dates.

Yes

No

Q16. For a targeted systemic Immunomodulators, Dermatologic, all of the following:

Is prescribed the targeted systemic Immunomodulators, Dermatologic by or in consultation with an appropriate specialist (e.g., dermatologist).

If currently using a different targeted systemic Immunomodulators, Dermatologic, will discontinue the other targeted systemic Immunomodulators, Dermatologic prior to starting the requested targeted systemic Immunomodulators, Dermatologic.

Q17. For treatment of chronic atopic dermatitis, has atopic dermatitis associated with at least one of the following:

A body surface area of 10% or greater that is affected.

Involvement of critical areas (e.g., face, feet, genitals, hands, intertriginous areas, scalp)

Significant disability or impairment of physical, mental, or psychosocial functioning

Q18. The member has a history of therapeutic failure of or a contraindication or an intolerance to both of the following:

A four-week trial of a topical corticosteroid approved or medically accepted for the treatment of the beneficiary's diagnosis

An eight-week trial of a topical calcineurin inhibitor approved or medically accepted for the treatment of the beneficiary's diagnosis

Q19. For treatment of prurigo nodularis, has a history of pruritis lasting at least six weeks.

Yes

No

Q20. The member has prurigo nodularis associated with at least one of the following:

Greater than or equal to 20 nodular lesions

Significant disability or impairment of physical, mental, or psychosocial functioning

## Immunomodulators - Dermatologics

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Member Name:	Prescriber Name:
--------------	------------------

Q21. For treatment of all other diagnoses, the member has a history of therapeutic failure of or a contraindication or an intolerance to first-line therapy(ies) if applicable according to current consensus treatment guidelines.

Yes

No

Q22. For an oral JAK inhibitor, the member meets one of the following:

- Has a history of therapeutic failure of at least one biologic if recommended for the beneficiary's diagnosis in the FDA-approved package labeling for the requested oral JAK inhibitor
- Has a contraindication or an intolerance to biologics if recommended for the beneficiary's diagnosis in the FDA-approved package labeling for the requested oral JAK inhibitor
- Has a current history (within the past 90 days) of being prescribed an oral JAK inhibitor

Q23. For a non-preferred targeted systemic Immunomodulators, Dermatologic, one of the following:

- |  |   |
|--|---|
| <input type="checkbox"/> Has a history of therapeutic failure of or a contraindication or an intolerance to the preferred targeted systemic Immunomodulators, Dermatologics approved or medically accepted for the beneficiary's diagnosis | <input type="checkbox"/> Has a current history (within the past 90 days) of being prescribed the same targeted systemic Immunomodulators, Dermatologic (does not apply to non-preferred targeted systemic Immunomodulators, Dermatologics when a therapeutically equivalent brand/generic or corresponding biosimilar/brand biologic/unbranded biologic is preferred) |
|--|---|

Q24. The member has documented evidence of improvement of disease severity.

Yes

No

Q25. The member is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature.

Yes

No

Q26. The member does not have a contraindication to the requested drug.

Yes

No

## Immunomodulators - Dermatologics

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Member Name:	Prescriber Name:
--------------	------------------

Q27. The request is for a PREFERRED topical PDE4 inhibitor, topical JAK inhibitor, topical AhR agonist

Yes  No

Q28. What type of drug is being requested?

For a non-preferred topical calcineurin inhibitor, go to 29.

For a non-preferred topical PDE4 inhibitor (e.g., crisaborole, roflumilast), go to 30.

For a non-preferred topical JAK inhibitor (e.g., ruxolitinib), go to 31.

For a non-preferred topical AhR agonist (e.g., tapinarof), go to 32.

For all other non-preferred topical Immunomodulators, Dermatologics, go to 33.

For a targeted systemic Immunomodulators, Dermatologic, go to 34.

Q29. For a non-preferred topical calcineurin inhibitor, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred topical calcineurin inhibitors.

Yes  No

Q30. For a non-preferred topical PDE4 inhibitor, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred topical PDE4 inhibitors approved or medically accepted for the beneficiary's diagnosis.

Yes  No

Q31. For a non-preferred topical JAK inhibitor, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred topical JAK inhibitors approved or medically accepted for the beneficiary's diagnosis.

Yes  No

Q32. For a non-preferred topical AhR agonist, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred topical AhR agonists approved or medically accepted for the beneficiary's diagnosis.

Yes  No



**MEDICAID / CHIP**  
**PHARMACY PRIOR AUTHORIZATION REQUEST FORM**

**Immunomodulators - Dermatologics**

**Phone: 866-841-7659**

**Fax back to: 866-240-3712**

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Member Name:	Prescriber Name:
--------------	------------------

Q33. For all other non-preferred topical Immunomodulators, Dermatologics, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred topical Immunomodulators, Dermatologics approved or medically accepted for the beneficiary's diagnosis.

Yes

No

Q34. For a targeted systemic Immunomodulator, Dermatologics, both of the following:

Is prescribed the targeted systemic Immunomodulators, Dermatologic by or in consultation with an appropriate specialist (e.g., dermatologist)

For a non-preferred targeted systemic Immunomodulators, Dermatologic with a therapeutically equivalent brand/generic or corresponding biosimilar/brand biologic/unbranded biologic that is preferred on the PDL, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred therapeutically equivalent brand/generic or corresponding biosimilar/brand biologic/unbranded biologic that would not be expected to occur with the requested drug.

Q35. Additional Information:

\_\_\_\_\_  
Prescriber Signature

\_\_\_\_\_  
Date

v2026-06